Literature DB >> 18070216

Incidence of fatal adverse drug reactions: a population based study.

Karin Wester1, Anna K Jönsson, Olav Spigset, Henrik Druid, Staffan Hägg.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Although drugs generally are safe and effective therapies for numerous diseases, adverse drug reactions do occur and may even be fatal. * The incidence of fatal adverse drug reactions in hospitalized patients has been estimated to be approximately 5%. * In previous studies the incidence of fatal adverse drug reactions in hospitalized patients has been reported, but the incidence of fatal adverse drug reactions in the general population is largely unknown. WHAT THIS STUDY ADDS: * Fatal adverse drug reactions account for approximately 3% of all deaths in the general population. * Haemorrhages amount to almost two-thirds of the fatal adverse drug reactions and antithrombotic agents are implicated in more than half of the suspected fatal adverse drug reactions. * Fatal adverse drug reactions are estimated to be the seventh most common cause of death in Sweden. AIMS: To determine the incidence of fatal adverse drug reactions (FADRs) in a Swedish population.
METHODS: Every seventh randomly selected deceased in three counties in South-east Sweden during 1 January 2001-31 December 2001 was identified in the Cause of Death Register. Relevant case records (hospitals and/or primary care centres and medicolegal files) were reviewed to identify suspected drug-related fatalities.
RESULTS: Of 1574 deceased study subjects, 49 (3.1%; 95% CI 2.2%, 4.0%) were suspected to have died from FADRs. The most common suspected FADRs were gastrointestinal haemorrhages (n = 18; 37%), central nervous system haemorrhages (n = 14; 29%), cardiovascular disorders (n = 5; 10%), other haemorrhages (n = 4; 8%) and renal dysfunction (n = 3; 6%). The drugs most commonly implicated in FADRs were antithrombotic drugs (n = 31; 63%), followed by nonsteroidal anti-inflammatory drugs (NSAIDs) (n = 9; 18%), antidepressants (n = 7; 14%) and cardiovascular drugs (n = 4; 8%). Of all the 639 fatalities in hospital 41 (6.4%; 95% CI 4.5%, 8.3%) were suspected to be due to FADRs.
CONCLUSIONS: The medical burden of FADRs is significant. Haemorrhages were seen in a majority of the FADRs; antithrombotic agents or NSAIDs were implicated in most of these events. These results suggest that preventive measures should be taken to reduce the number of deaths caused by drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070216      PMCID: PMC2291376          DOI: 10.1111/j.1365-2125.2007.03064.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Adverse drug reactions as a cause for admissions to a department of internal medicine.

Authors:  Tom Mjörndal; Marit Danell Boman; Staffan Hägg; Martin Bäckström; Bengt-Erik Wiholm; Anders Wahlin; Rune Dahlqvist
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Jan-Feb       Impact factor: 2.890

2.  Drug-related deaths in a university central hospital.

Authors:  L Juntti-Patinen; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2002-09-03       Impact factor: 2.953

3.  Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions.

Authors:  J Hasford; M Goettler; K-H Munter; B Müller-Oerlinghausen
Journal:  J Clin Epidemiol       Date:  2002-09       Impact factor: 6.437

4.  Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group.

Authors:  K J Belton
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

5.  Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden.

Authors:  Karin Wester; Anna Jönsson; Olav Spigset; Staffan Hägg
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-02       Impact factor: 2.890

6.  International drug monitoring: the role of national centres. Report of a WHO meeting.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1972

7.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

8.  Incidence of lethal adverse drug reactions in the comprehensive hospital drug monitoring, a 20-year survey, 1974-1993, based on the data of Berne/St. Gallen.

Authors:  M Zoppi; S Braunschweig; U P Kuenzi; R Maibach; R Hoigné
Journal:  Eur J Clin Pharmacol       Date:  2000-08       Impact factor: 2.953

9.  Drug-related deaths among medical inpatients.

Authors:  J Porter; H Jick
Journal:  JAMA       Date:  1977-02-28       Impact factor: 56.272

10.  Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study.

Authors:  Sebastian Schneeweiss; Joerg Hasford; Martin Göttler; Annemarie Hoffmann; Ann-Kathrin Riethling; Jerry Avorn
Journal:  Eur J Clin Pharmacol       Date:  2002-06-12       Impact factor: 2.953

View more
  98 in total

1.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

Review 2.  [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].

Authors:  J C Stingl; K S Just; K Kaumanns; M Schurig-Urbaniak; C Scholl; D von Mallek; J Brockmöller
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

3.  Patterns, predictors and preventability of adverse drug reactions in the coronary care unit of a tertiary care hospital.

Authors:  Padmini Devi; Deepak Y Kamath; Naveen Anthony; Sushma Santosh; Brendan Dias
Journal:  Eur J Clin Pharmacol       Date:  2011-10-19       Impact factor: 2.953

Review 4.  High yield research opportunities in geriatric emergency medicine: prehospital care, delirium, adverse drug events, and falls.

Authors:  Christopher R Carpenter; Manish N Shah; Fredric M Hustey; Kennon Heard; Lowell W Gerson; Douglas K Miller
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-04-17       Impact factor: 6.053

5.  Minimising harm: human variation and adverse drug reactions (ADRs).

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

6.  Pharmacogenetics and pharmacovigilance.

Authors:  Robert H Howland
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Polypharmacy, inappropriate prescribing and adverse drug reactions in Austria.

Authors:  Markus Müller
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

8.  A new approach to identify, classify and count drug-related events.

Authors:  Thomas Bürkle; Fabian Müller; Andrius Patapovas; Anja Sonst; Barbara Pfistermeister; Bettina Plank-Kiegele; Harald Dormann; Renke Maas
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

9.  Application of the Pareto principle to identify and address drug-therapy safety issues.

Authors:  Fabian Müller; Harald Dormann; Barbara Pfistermeister; Anja Sonst; Andrius Patapovas; Renate Vogler; Nina Hartmann; Bettina Plank-Kiegele; Melanie Kirchner; Thomas Bürkle; Renke Maas
Journal:  Eur J Clin Pharmacol       Date:  2014-03-21       Impact factor: 2.953

10.  Different black box warning labeling for same-class drugs.

Authors:  Orestis A Panagiotou; Despina G Contopoulos-Ioannidis; Panagiotis N Papanikolaou; Evangelia E Ntzani; John P A Ioannidis
Journal:  J Gen Intern Med       Date:  2011-02-01       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.